1st Jul 2009 08:01
Wednesday 1 July 2009
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Appointment of Directors, Directors Holdings and Total Voting Rights
AIM Rule Disclosure- Schedule 2(g)
Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that further to the announcement made by the Company on 12 June 2009, Alejandro Esteban Weinstein Manieu (51) and Manuel Llobet (45) were today appointed as directors of the Company.
In accordance with Rule 17 of the AIM Rules, the following information can be disclosed regarding Alejandro Weinstein and Manuel Llobet:
Alejandro Weinstein
|
Current directorships and partnerships |
Past directorships and partnerships within the last five years |
|
Genomika Foundation |
|
|
Laboratorios Recalcine S.A. |
|
|
Biomedical Research Consortium |
Manuel Llobet
|
Current directorships and partnerships |
Past directorships and partnerships within the last five years |
|
Drokasa Peru S.A. |
|
|
Gynopharm S.A. (Costa Rica) |
|
|
Gynopharm S.A. (Colombia) |
|
|
Laboratorios Elea México S.A. de C.V. |
|
|
Servicios Elche S.A. de C.V. |
|
|
Laboratorios Atlas |
|
|
Gynopharm de Venezuela C.A. |
|
|
Farmindustria S.A. |
There is no further information to be disclosed under Schedule 2(g) of the AIM Rules for Companies.
Directors' holdings
After Admission, the interests of the Directors and the percentage of the Company's issued share capital which they represent are as follows:
|
Number of Ordinary Shares |
% of Share Capital after Admission |
|
|
Keith I Carter |
3,192,669 |
1.21% |
|
Ignace R Goethals |
4,897,912 |
1.86% |
|
Ian Postlethwaite |
0 |
0.00% |
|
Tom Holdich |
0 |
0.00% |
|
Christian Gratz |
510,658 |
0.19% |
|
Stephen R Smith |
756,513 |
0.29% |
|
Virinder Nohria |
5,211 |
0.00% |
|
Alejandro Weinstein* |
0 |
0.00% |
|
Manuel Llobet** |
0 |
0.00% |
*Alejandro Weinstein is a beneficiary of Azure Ventures Limited, which is interested in 104,166,666 shares, 39.46% of the Company
** Manuel Llobet is a beneficiary of Wild Indigo S.A, which is interested in 3,125,000 shares, 1.18% of the Company
Total Voting Rights Following Admission
The Company's issued voting share capital is 263,998,551 ordinary shares of 0.1p each.
For further information
|
Allergy Therapeutics |
+44 (0) 1903 845 820 |
|
Keith Carter, Chief Executive |
|
|
www.allergytherapeutics.com |
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
|
Juliet Thompson/ Clare Terlouw |
|
|
Financial Dynamics |
+44 (0) 207 831 3113 |
|
Ben Brewerton/ Susan Quigley |
Related Shares:
Allergy Thera.